
    
      Lansoprazole is currently approved in Germany for the treatment of erosive reflux esophagitis
      and active duodenal and gastric ulcer disease, and for long-term treatment including
      maintenance of healed reflux esophagitis and duodenal ulcer disease and treatment of
      pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

      This study was conducted to evaluate the safety, efficacy and quality of life of patients
      receiving up to five years of treatment with lansoprazole.
    
  